CA2422814A1 - Cripto mutant and uses thereof - Google Patents

Cripto mutant and uses thereof Download PDF

Info

Publication number
CA2422814A1
CA2422814A1 CA002422814A CA2422814A CA2422814A1 CA 2422814 A1 CA2422814 A1 CA 2422814A1 CA 002422814 A CA002422814 A CA 002422814A CA 2422814 A CA2422814 A CA 2422814A CA 2422814 A1 CA2422814 A1 CA 2422814A1
Authority
CA
Canada
Prior art keywords
seq
cripto
polypeptide
amino acid
full length
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002422814A
Other languages
English (en)
French (fr)
Inventor
Kevin P. Williams
Susan Foley
Susan Schiffer
Bruno Domon
Michele Sanicola-Nadel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2422814A1 publication Critical patent/CA2422814A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002422814A 2000-09-18 2001-09-18 Cripto mutant and uses thereof Abandoned CA2422814A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23314800P 2000-09-18 2000-09-18
US60/233,148 2000-09-18
PCT/US2001/029066 WO2002022808A2 (en) 2000-09-18 2001-09-18 Cripto mutant and uses thereof

Publications (1)

Publication Number Publication Date
CA2422814A1 true CA2422814A1 (en) 2002-03-21

Family

ID=22876077

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002422814A Abandoned CA2422814A1 (en) 2000-09-18 2001-09-18 Cripto mutant and uses thereof

Country Status (7)

Country Link
US (1) US7604931B2 (https=)
EP (1) EP1320604A2 (https=)
JP (1) JP2004524810A (https=)
AU (2) AU9272401A (https=)
CA (1) CA2422814A1 (https=)
NZ (1) NZ525380A (https=)
WO (1) WO2002022808A2 (https=)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123470A1 (en) * 2001-03-26 2009-05-14 The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. Antibodies Against Cancer
AUPR395801A0 (en) * 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
PT1390389E (pt) * 2001-04-26 2009-04-03 Biogen Idec Inc Anticorpos que bloqueiam o cripto e as utilizações dos mesmos
CA2539116C (en) 2003-09-15 2014-11-18 Research Development Foundation Cripto antagonism of activin and tgf-b signaling
US20070122813A1 (en) * 2003-10-03 2007-05-31 David Salomon Use of cripto-1 as a biomarker for neurodegenerative disease and method of inhibiting progression thereof
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
ES2408704T3 (es) 2005-01-05 2013-06-21 Biogen Idec Ma Inc. Moléculas de unión a Cripto
WO2006074341A2 (en) * 2005-01-07 2006-07-13 Glaxo Group Limited Novel use
AU2007243181A1 (en) * 2006-04-28 2007-11-08 Biogen Idec Ma Inc. Composition and methods for the detection of Cripto-3
AU2007248253B2 (en) * 2006-05-02 2010-12-23 Genentech, Inc. Microwave assisted deglycosylation of proteins for molecular weight determination by mass spectrometry
WO2008040759A1 (en) * 2006-10-03 2008-04-10 Pharmexa A/S Method for down-regulation of cripto
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
DK2528625T3 (da) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepiner og konjugater deraf
BR112012030311A2 (pt) 2010-06-08 2017-01-24 Genentech Inc anticorpo
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
KR101992502B1 (ko) 2011-05-12 2019-06-24 제넨테크, 인크. 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법
JP6104257B2 (ja) 2011-10-14 2017-03-29 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピンおよびそのコンジュゲート
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
ES2649990T3 (es) 2012-10-12 2018-01-16 Medimmune Limited Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
AU2013328625B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN105189507A (zh) 2012-12-21 2015-12-23 斯皮罗根有限公司 吡咯并苯并二氮杂卓及其结合物
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
NZ710746A (en) 2013-03-13 2018-11-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
SG11201507214SA (en) 2013-03-13 2015-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3033111B1 (en) 2013-08-12 2019-03-13 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
JP6671292B2 (ja) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
KR20170042495A (ko) 2013-12-16 2017-04-19 제넨테크, 인크. 펩티드모방체 화합물 및 그의 항체-약물 접합체
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US20160074527A1 (en) 2014-09-17 2016-03-17 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
MX2017007169A (es) 2014-12-03 2018-05-02 Genentech Inc Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos.
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CA2996902C (en) 2015-10-02 2020-06-02 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EP3362100B1 (en) 2015-10-16 2022-06-22 Genentech, Inc. Hindered disulfide drug conjugates
EP3365025B1 (en) 2015-10-20 2020-07-15 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
MX375569B (es) 2017-02-08 2025-03-04 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
PT3612537T (pt) 2017-04-18 2022-08-29 Medimmune Ltd Conjugados de pirrolobenzodiazepina
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
DK3668874T3 (da) 2017-08-18 2022-02-14 Medimmune Ltd Pyrrolobenzodiazepin-konjugater
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP7708662B2 (ja) 2018-10-24 2025-07-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
KR102890251B1 (ko) 2019-03-15 2025-11-25 메드임뮨 리미티드 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
IT202200007580A1 (it) * 2022-04-15 2023-10-15 Consiglio Nazionale Ricerche Vescicole lipidiche per l’uso nel trattamento terapeutico di tumori aggressivi
EP4637833A2 (en) 2022-12-23 2025-10-29 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
EP4698230A2 (en) 2023-04-17 2026-02-25 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256643A (en) * 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5264557A (en) * 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
KR19980703534A (ko) * 1995-06-05 1998-11-05 벤슨로버트에이치 사람 크립틴 성장 인자
DE69737457T2 (de) * 1997-01-31 2007-11-29 Genentech, Inc., South San Francisco O-fukosyltransferase
JP2002505338A (ja) * 1998-03-05 2002-02-19 カイロン コーポレイション 生物学的に活性な分子の血清半減期を増加するための方法
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines

Also Published As

Publication number Publication date
JP2004524810A (ja) 2004-08-19
US20030232755A1 (en) 2003-12-18
EP1320604A2 (en) 2003-06-25
AU9272401A (en) 2002-03-26
AU2001292724B2 (en) 2005-05-26
WO2002022808A3 (en) 2003-01-16
NZ525380A (en) 2008-06-30
WO2002022808A2 (en) 2002-03-21
US7604931B2 (en) 2009-10-20

Similar Documents

Publication Publication Date Title
US7604931B2 (en) Cripto mutant and uses thereof
AU2001292724A1 (en) CRIPTO mutant and uses thereof
KR101220245B1 (ko) 성장인자에 결합하는 융합 단백질
KR100611620B1 (ko) 안지오포이에틴 수용체 결합 도메인 및 다중체화 도메인을포함하는 융합 단백질
AU728614B2 (en) Cerebellum-derived growth factors, and uses related thereto
Wen et al. Structural and functional aspects of the multiplicity of Neu differentiation factors
Schaefer et al. γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175
JP4793836B2 (ja) 線維芽細胞増殖因子様ポリペプチド
EP0599274A1 (en) HER4, a human receptor tyrosine kinase of the epidermal growth factor receptor family
WO1997009425A9 (en) Cerebellum-derived growth factors, and uses related thereto
IL126918A (en) Ret ligand (retl) for stimulating neural and renal growth
IL124859A (en) Nucleic acid molecules encoding the active portion of human agrin, active portion of human agrin and uses thereof
AU735794B2 (en) Don-1 gene and polypeptides and uses therefor
Lorenzi et al. FRAG1, a gene that potently activates fibroblast growth factor receptor by C-terminal fusion through chromosomal rearrangement.
WO2000037642A1 (en) Method of enhancing the biological activity of ligands
CN102134275B (zh) 表皮生长因子受体变异体
AU2005204268B2 (en) CRIPTO Mutant and Uses Thereof
HU211976A9 (en) The ciliary neurotrophic factor receptor
AU2007200329A1 (en) CRIPTO Mutant and Uses Thereof
CA2202533A1 (en) Her4 human receptor tyrosine kinase
Wu Tumorigenesis of A431 human epidermoid carcinoma cell
WEN et al. ROD L. CUPPLES, l YILUO, 1 ANN M. JANSSEN, l NOA BEN-BARUCH, 2 DAVID B. TROLLINGER, l

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead